Pharming Group NV
$ 10.95
0.92%
07 Aug - close price
- Market Cap 775,020,000 USD
- Current Price $ 10.95
- High / Low $ 11.15 / 10.89
- Stock P/E 78.21
- Book Value 3.61
- EPS 0.14
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.03 %
- ROE 0.04 %
- 52 Week High 21.34
- 52 Week Low 9.62
About
Pharming Group NV, a specialty pharmaceutical company, develops products for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company is headquartered in Leiden, the Netherlands.
Analyst Target Price
$34.35
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-07-30 | 2026-05-07 | 2026-03-12 | 2025-11-06 | 2025-07-31 | 2025-05-08 | 2025-03-13 | 2024-10-24 | 2024-08-01 | 2024-05-08 | 2024-03-14 | 2023-10-26 |
| Reported EPS | 0.02 | -0.07 | 0.07 | 0.01 | 0.01 | -0.02 | 0.005 | -0.0153 | -0.0177 | -0.02 | -0.0406 | 0.01 |
| Estimated EPS | 0.2 | 0.01 | 0.0117 | -0.125 | -0.01 | -0.02 | 0.0085 | -0.0025 | -0.002 | 0.01 | 0.0045 | -0.01 |
| Surprise | -0.18 | -0.08 | 0.0583 | 0.135 | 0.02 | 0 | -0.0035 | -0.0128 | -0.0157 | -0.03 | -0.0451 | 0.02 |
| Surprise Percentage | -90% | -800% | 498.2906% | 108% | 200% | 0% | -41.1765% | -512% | -785% | -300% | -1002.2222% | 200% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: PHAR
2026-08-07 23:10:26
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Pharming Group N.V. (NASDAQ: PHAR) following a significant drop in its stock price. The investigation stems from the company's lowered full-year 2026 revenue guidance and weaker-than-expected RUCONEST sales, raising concerns about whether competitive and demand pressures were adequately disclosed to investors. The firm is encouraging affected investors to join the investigation.
2026-08-07 19:10:26
This page provides real-time stock news for Pharming Group NV (PHAR), including its current stock price, market capitalization, and links to financial data and analyst ratings. The article notes that more news will be coming soon, indicating that the content is updated regularly. It also includes contact information for content collaboration and user feedback.
2026-08-07 09:43:29
Glancy Prongay Wolke & Rotter LLP has launched an investigation into Pharming Group N.V. (NASDAQ: PHAR) following a significant drop in its stock price. The investigation concerns potential violations of federal securities laws after the company reported a year-over-year revenue decline and cut its full-year revenue guidance. Shareholders who incurred losses are encouraged to contact the law firm to explore potential claims.
2026-08-06 19:10:26
The Law Offices of Frank R. Cruz have announced a securities fraud investigation into Pharming Group N.V. (PHAR) following the company's recent second-quarter earnings report, which showed a revenue decline and a cut in full-year guidance. Shareholders who lost money after the stock fell 10.5% on July 30, 2026, are encouraged to contact the firm to inquire about potentially pursuing a claim. The investigation focuses on possible violations of federal securities laws by Pharming.
2026-08-06 09:42:04
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Pharming Group N.V. (PHAR) following a significant drop in its stock price. This comes after the company reported a 3% year-over-year revenue decline in Q2 2026 and lowered its full-year guidance, largely due to weaker-than-expected RUCONEST sales. The investigation focuses on whether Pharming Group adequately disclosed competitive and demand pressures affecting RUCONEST before revising its guidance, which led to a 22% stock price drop.
2026-08-05 15:16:00
The Law Offices of Frank R. Cruz have announced a securities fraud investigation into Pharming Group N.V. (PHAR) on behalf of investors who lost money. The investigation follows a 10.5% stock drop after the company reported a 3.2% year-over-year revenue decline and cut its full-year revenue guidance. Shareholders are urged to contact the law firm to learn about potentially pursuing a claim.
